docetaxel

You have access
Matrix metalloproteinase-2 and -14 in p16-Positive and -Negative HNSCC after Exposure To 5-FU and Docetaxel In Vitro
CHRISTOPH ADERHOLD, CLAUDIA UMBREIT, ANNE FABER, RICHARD BIRK, JÖRG ULRICH SOMMER, KARL HÖRMANN and JOHANNES DAVID SCHULTZ

Anticancer Research September 2014, 34 (9) 4929-4937;
You have access
Phase II Study of Docetaxel-plus-Bevacizumab Combination Therapy in Patients Previously Treated for Advanced Non-squamous Non-small Cell Lung Cancer
FUMIYOSHI OHYANAGI, NORIKO YANAGITANI, KEITA KUDO, YUKO KAWANO, TOSHIO SAKATANI, AZUSA TANIMOTO, HIRONARI NISHIZAWA, ATSUSHI HORIIKE, SACHIKO HAGIWARA, TAKESHI HORAI and MAKOTO NISHIO

Anticancer Research September 2014, 34 (9) 5153-5158;
You have access
Synergistic Antitumor Effect of NVP-BEZ235 and Sunitinib on Docetaxel-resistant Human Castration-resistant Prostate Cancer Cells
HONG SEOK PARK, SUNG KYU HONG, MI MI OH, CHEOL YONG YOON, SEONG JIN JEONG, SEOK SOO BYUN, JUN CHEON, SANG EUN LEE and DU GEON MOON

Anticancer Research July 2014, 34 (7) 3457-3468;
You have access
Docetaxel/ TS-1 with Radiation for Unresectable Squamous Cell Carcinoma of the Esophagus - A Phase II Trial
HIDEO MATSUMOTO, HISAKO KUBOTA, MASAHARU HIGASHIDA, EISAKU YODEN, JUNICHI HIRATSUKA, KEN HARUMA, MASAFUMI NAKAMURA and TOSHIHIRO HIRAI

Anticancer Research July 2014, 34 (7) 3759-3763;
You have access
Early Predictive Value of Non-response to Docetaxel in Neoadjuvant Chemotherapy in Breast Cancer Using ¹⁸F-FDG-PET
TOMOKO HIRAKATA, YASUHIRO YANAGITA, TOMOMI FUJISAWA, TAKAAKI FUJII, TERUHIKO KINOSHITA, HIROYUKI HORIKOSHI, NARIYUKI OYA, TSUKASA AKIYOSHI, MISA IIJIMA, TAKESHI MIYAMOTO and HIROYUKI KUWANO

Anticancer Research January 2014, 34 (1) 221-226;
You have access
An ELCWP Phase III Trial Comparing Ifosfamide and Cisplatin Regimens in Advanced NSCLC
THIERRY BERGHMANS, JEAN-JACQUES LAFITTE, ARNAUD SCHERPEREEL, MARIANNE PAESMANS, JACQUES LECOMTE, VICENTE GINER MARCO, ANNE-PASCALE MEERT, NATHALIE LECLERCQ, JEAN-PAUL SCULIER and for the European Lung Cancer Working Party

Anticancer Research December 2013, 33 (12) 5477-5482;
You have access
A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity
SOPHIE GOUÉRANT, MARIANNE LEHEURTEUR, MAHER CHAKER, ROMAIN MODZELEWSKI, OLIVIER RIGAL, CORINNE VEYRET, GÉRALDINE LAURIDANT and FLORIAN CLATOT

Anticancer Research December 2013, 33 (12) 5655-5662;
You have access
Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer
MASAAKI KAWAHARA, SHINJI ATAGI, KIYOSHI KOMUTA, HIROSHIGE YOSHIOKA, MASAYUKI KAWASAKI, YUKA FUJITA, TOSHIRO YONEI, FUMITAKA OGUSHI, KAORU KUBOTA, NAOYUKI NOGAMI, MICHIKO TSUCHIYA, KAZUHIKO SHIBATA, YOSHIO TOMIZAWA, KOICHI MINATO, KAZUYA FUKUOKA, KAZUHIRO ASAMI, TAKEHARU YAMANAKA and THE JAPAN MULTINATIONAL TRIAL ORGANIZATION

Anticancer Research October 2013, 33 (10) 4631-4637;
You have access
High Efficacy of Chemoradiation Therapy Sensitized by Weekly Docetaxel for Anaplastic Thyroid Cancer
NAOYOSHI ONODA, SHINICHIRO KASHIWAGI, SATORU NODA, HIDEMI KAWAJIRI, TSUTOMU TAKASHIMA, TETSURO ISHIKAWA and KOSEI HIRAKAWA

Anticancer Research August 2013, 33 (8) 3445-3448;
You have access
Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract
AYSEGÜL ILHAN-MUTLU, MATTHIAS PREUSSER, SEBASTIAN F. SCHOPPMANN, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, URSULA PLUSCHNIG, PETER BIRNER, ANDREAS PÜSPÖK, JOHANNES ZACHERL and MICHAEL HEJNA

Anticancer Research August 2013, 33 (8) 3455-3459;

Main menu

User menu

Search

docetaxel

Pages